Medicenna Therapeutics Engages with Investors at Upcoming Conferences
Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF) is set to showcase its commitment to advancing cancer immunotherapies by participating in two significant investor conferences next month. Based in Toronto and Houston, Medicenna is a pioneering clinical-stage immunotherapy company that concentrates on the development of Superkines aimed at treating cancer, alongside inflammatory and autoimmune conditions.
Oppenheimer Annual Healthcare Life Sciences Conference
Presentation Overview
One of the highlight events will be the Oppenheimer Annual Healthcare Life Sciences Conference, where Medicenna management will deliver a presentation. This crucial engagement is scheduled for February 11, 2025, taking place at 9:20 a.m. ET. The presentation aims to provide investors with insights into Medicenna's innovative strategies and the promising potential of its therapeutic platforms.
Access to Webcast
Interested investors and stakeholders can access the webcast of this event, with full details to be available in the investor relations section of Medicenna’s website. A replay of the presentation will remain accessible for 180 days post-event, ensuring that all interested parties can keep up with the advancements and updates from the Company.
B. Riley Securities Precision Oncology Conference
Fireside Chat Format
Following the Oppenheimer conference, Medicenna will also participate in the B. Riley Securities Precision Oncology & Radiopharma Conference on February 28, 2025. This event will feature a fireside chat format, allowing for an engaging discussion about Medicenna’s cutting-edge approaches in the oncology space. This unique setting will foster a direct dialogue between the Company and potential investors, enabling a deeper understanding of their clinical advancements.
One-on-One Meetings with Investors
In addition to the presentations at these conferences, Medicenna’s management team will be available for personalized one-on-one meetings with investors. This effort underscores Medicenna’s commitment to transparency and investor engagement, offering an invaluable opportunity for tailored discussions about the Company’s future and investment potential. Interested investors are encouraged to schedule meetings through their conference representatives or via Medicenna’s investor relations team.
The Therapeutic Innovations at Medicenna
Medicenna is at the forefront of immunotherapy development, particularly focused on creating highly selective versions of interleukins including IL-2, IL-4, and IL-13 Superkines. Their notable candidate, MDNA11, is a next-generation IL-2 Superkine with a unique binding profile that preferentially stimulates critical cancer-fighting immune cells, making it a strong contender in current clinical evaluations.
Clinical Studies and Regulatory Approvals
MDNA11 is currently being investigated within the Phase 1/2 ABILITY-1 study as both a standalone treatment and in combination with pembrolizumab, a checkpoint inhibitor. In addition, Medicenna has made significant strides with its IL-4 Empowered Superkine, bizaxofusp, which has been the focus of multiple clinical trials and has received Fast Track and Orphan Drug designations from the FDA, enhancing its potential in treating recurrent glioblastoma, a notoriously aggressive brain cancer.
Looking Ahead
Medicenna’s pipeline also includes early-stage IL-2/IL-15 Super-antagonists and innovative therapeutic platforms designed to target unmet needs in autoimmune diseases and cancers often characterized as immunologically “cold.” With a robust commitment to research and development, Medicenna aims to restructure the current landscape of oncology therapy.
Frequently Asked Questions
What is Medicenna Therapeutics focused on?
Medicenna is an immunotherapy company concentrating on developing Superkines for treating cancer and autoimmune diseases.
When will Medicenna participate in the upcoming investor conferences?
Medicenna is participating in two investor conferences in February 2025, including the Oppenheimer Annual Healthcare Life Sciences Conference and B. Riley Securities Precision Oncology Conference.
How can investors access Medicenna's presentations?
Investors can access the webcast related to Medicenna's presentations via the investor relations section of their website, with replays available for 180 days after the events.
What is the significance of MDNA11?
MDNA11 is a novel IL-2 Superkine, showing promise due to its superior affinity for cancer-fighting immune cells, which is currently being tested in clinical trials.
How can investors arrange meetings with Medicenna's management?
Investors interested in one-on-one meetings can contact their respective conference representatives or reach out to Medicenna’s investor relations team.
